- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: Public Health Initiatives Are Underfunded in the US
What we're reading, December 14, 2015: public health initiatives are underfunded despite being a big return on investment; the FDA repeatedly approved the cancer drug Afinitor without proof it extended life; and a nurse may have exposed patients in a maternity wing to tuberculosis.
Although public health initiatives have a big return on investment, only 3 cents of each US healthcare dollar goes to public health, according to Karen DeSalvo, MD, MPH, MSc, HHS acting assistant secretary for health. USA Today reported that Dr DeSalvo said at a forum that 97% of funding goes to medical services even though 80% of people’s health is influenced by their lives outside of the doctor’s office.
The FDA continues to approve drugs without proof that they are extending a patient’s life, according to a report in the Milwaukee Journal Sentinel. An analysis of the cancer drug Afinitor found that the treatment was repeatedly approved by the FDA for new uses over 6 years. However, the drug comes with a long list of side effects, nearly 1 in 5 patients develop a potentially fatal lung condition, and there have been thousands of reports of serious adverse reactions, deaths, and hospitalizations.
In California, a nurse with tuberculosis in a maternity wing may have exposed more than 1000 people, including 350 infants. The risk of infection has remained low, but all patients, staff members, and visitors who have been exposed are being notified. Screenings have begun, but so far no one has tested positive for the disease, reported The New York Times.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
